Applications for Accelerate@Babraham, designed to support early stage life science ventures, will close on June 17th 2020.
The Accelerate@Babraham initiative is designed to support ambitious early stage life science ventures. It does this by giving access to appropriate short-term open access laboratory and office space, facilitating interaction with the academic community at the Babraham Institute and providing access to our global network, including mentoring and business support.
A key activity within the Accelerate@Babraham initiative is the annual StartUP@Babraham competition. The…
Hints and Tips for Working from Home by george james ltd
Working from home is a new experience for many people, and even those of us who have worked at home on and off for many years have probably not done so for such an extended period. For some people working at home may become the new norm.
george james ltd have put together some hints and tips that we hope you find helpful.
By visiting the knowledge base section of our website you can find links to 2 videos and one downloadable aide-memoir: http://georgejamesltd.com/free-knowledge-base/training-and-development/
Video1: 10 Tips for…
Cambridge, UK: 14 April 2020: Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibody therapeutics, announces that Regeneron Pharmaceuticals Inc (“Regeneron”) has been unsuccessful in recent attempts to invalidate four of Kymab’s US patents covering genetically modified mice and the human antibody therapeutics produced from these mice. The patents are US patent numbers 9,434,782; 9,505,827; 9,447,177; and 10,165,763 known as the “Bradley Patents”. Equivalent patents have been granted by the European Patent Office and in other jurisdictions including Japan…
New England Biolabs is working diligently to ensure we keep our employees and their families safe, while maintaining our business continuity in support of our many customers around the globe. Our manufacturing and distribution teams continue to be fully operational, and we are working closely with our suppliers and distribution partners to ensure uninterrupted access to our products and technical support. We are also following the guidelines of local and national health organizations in order to mitigate the spread of COVID-19. If you have any questions or concerns, please feel free to…
The MagSi-NA Pathogens Kit from AMSBIO enables easy extraction of DNA and RNA from serum, plasma, oropharyngeal swab / nasopharyngeal swab, and any other respiratory samples for pathogen detection.The kit is particularly suitable for total nucleic acid extraction for SARS-CoV-2 / COVID-19 detection, currently a major bottleneck in COVID-19 testing.Due to the kit’s simple protocol and ready-to-use-agents, it is easy to scale to small, medium, and high-throughput automation, yielding highly pure nucleic acid in small elution volumes. The MagSi-NA…
Dear Friends, Colleagues and Supporters of NHS staff, We are seeking donations to the Cambridge China COVID-19 Collaboration (4C) Appeal which is an official part of the University of Cambridge COVID-19 appeal.
This appeal is led by two doctors and University of Cambridge Professors, Toni Vidal Puig and Sadaf Farooqi. Our aim is to ensure that high-grade Personal Protective Equipment (PPE) is available for health and social care professionals, caring for patients with COVID-19 in Cambridge and the East of England. We want to guarantee the safety and protection of our staff on the…
Cambridge, UK, 07 April 2020: Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, today announced it has contributed to two new peer-reviewed papers under the U.S. Food and Drug Administration’s (FDA) CiPA (Comprehensive in vitro Proarrhythmia Assay) initiative. The papers, in Nature Scientific Reports1 and Toxicology and Applied Pharmacology2, focus on application of improved cardiac safety testing protocols and recommendations for best practice for the drug discovery industry.
The CiPA Initiative (www.cipaproject.org), which began in July 2013…
Westbury, NY – Apr. 6, 2020 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced the opening of its new blood donor center on the Tufts University campus in Medford, MA to support academic and pharmaceutical researchers involved in COVID-19, cell and gene therapy research.
“BioIVT wants to play a leading role in supporting COVID-19 research efforts and blood donations are a vital resource for the research and development of new therapies, vaccines, and diagnostics. We have many years’ experience developing blood products, including…
tranScrip (www.transcrip-partners.com) is delighted to be supporting Synairgen with their first patient dosing in a trial of SNG001 in COVID-19.
tranScrip's support in this important endeavour is a continuation of being at the heart of the development of SNG001 (inhaled formulation of interferon-beta-1a) for the last 12 years.
Dr Marcin Mankowski, Deputy Managing Partner and Head of tranScrip’s ID Team, commented: “tranScrip has collaborated with Synairgen for many years, supporting the development of SNG001 to address an important medical need in the treatment of viral exacerbations of…
Cambridge, UK - 6 April 2020 - Healx, the AI-powered, patient-inspired biotech specialising in rare diseases, today announces it is using its AI platform to develop drug combinations from approved drugs to contribute towards global efforts to find treatments for COVID-19. This focus on combination therapies, where two or more drugs simultaneously target different aspects of the disease pathology, has the potential to ensure a more effective treatment.
Combination therapies are particularly difficult to discover. To uncover potential combination treatments for COVID-19 requires detailed…